US life sciences companies routinely sequence global filings on commercial intuition: New Drug Application (NDA) or Biologics License Application (BLA) to the FDA first, because Phase III data lands in the US format and the priority-review timelines are familiar; then Swissmedic, because Switzerland’s review windows are short and the pricing dynamics are favorable; then the EMA, because Europe is the largest single market but also the slowest. The EU Pharma Package’s compromise text, agreed at trilogue on 11 December 2025 and published in consolidated Council form in early March 2026, embeds a hard 90-day window inside that sequence. Filing the EU marketing authorisation application later than 90 days after any first non-Union filing forfeits a full year of EU market protection that would otherwise have been available, on conditions that turn out to have been fixed during pivotal-trial protocol design three to five years earlier. The analysis first maps the new protection architecture that anchors this Pharma Package series, then narrows to the 90-day rule itself: what “first marketing authorisation application outside the Union” means under the new text, which co-conditions travel with the trigger, and how the rule recalibrates the Swiss-versus-FDA-first decision that has historically been treated as jurisdictionally independent.
1. The Centerpiece: The 8+1 Baseline, the Modular Bonuses, and the 11-Year Cap
The reform of the EU’s regulatory protection framework is the architectural centerpiece of the EU Pharma Package, and US in-house counsel reading it for the first time will instinctively reach for the Hatch-Waxman framework as the closest US analogue. Under 21 U.S.C. § 355(j)(5)(F)(ii), new-chemical-entity exclusivity runs for five years from FDA approval; an additional three years are available under 21 U.S.C. § 355(j)(5)(F)(iii) for an abbreviated new drug application referencing a supplement supported by new clinical investigations essential to approval (the three-year clock attaches per qualifying supplement and runs from the supplement’s own approval date, rather than stacking onto the five-year NCE clock); seven years apply under the Orphan Drug Act, narrowed at the start of 2026 to the same approved use or indication within the rare disease or condition.121 U.S.C. § 355(j)(5)(F)(ii) (NCE exclusivity) and (F)(iii) (per-supplement NCI exclusivity); 21 U.S.C. § 360cc as amended by the Consolidated Appropriations Act, 2026, Pub. L. 119-75 (3 February 2026); FDA Draft Guidance on three-year NCI exclusivity (March 2026).
The European architecture is structurally different. The analysis here is anchored to the Council’s compromise text published in early March 2026 (ST-6367/26 for the revised Directive, ST-6366/26 for the companion Regulation) implementing the trilogue political agreement of 11 December 2025; it pre-dates Official Journal publication and the EMA scientific guidelines that several operative provisions envisage. Per the trilogue political agreement, the new baseline is eight years of regulatory data protection (during which no subsequent applicant may rely on the originator’s clinical data) plus one year of regulatory market protection (during which a subsequent application can be submitted and assessed but the product cannot reach the market), commonly referred to as the 8+1 baseline; the compromise text’s Art. 80 of the Directive frames both periods, with several visible trackchanges-flattened drafting layers on the precise numerical components.2Council compromise text for the revised Directive, Council doc ST-6367/26 (24 February 2026), Art. 80–83; European Parliament press release (11 December 2025) confirming 8+1 baseline and 11-year combined cap.
Both clocks anchor to the initial marketing authorisation under the global-marketing-authorisation concept of Art. 5(2) of the Directive, which means that later additional therapeutic indications, new strengths, new pharmaceutical forms, new routes of administration, and other variations are all part of the same global MA and do not extend the underlying RDP clock; US in-house counsel trained on Hatch-Waxman’s per-supplement NCI architecture should expect the EU framework to behave the opposite way at the line-extension point. The cumulative 8+1 EU baseline is one year longer than the US 5+3 NCE-plus-NCI ceiling at the floor, and meaningfully longer at the optimised maximum, where stacked prolongations push the protected duration up to the trilogue’s 11-year combined cap.
The reform is also not yet live. The Directive enters into force only on the twentieth day after Official Journal publication, and the new protection periods apply prospectively from a date of application that the compromise text still leaves bracketed at eighteen to twenty-four months after entry into force. By the Art. 218(5) of the Directive transitional derogation, reference medicinal products whose marketing authorisation application was submitted before that date remain subject to the data-protection periods of Art. 10 of Directive 2001/83/EC, the existing 8+2(+1) regime. The 90-day rule therefore governs the applications a sponsor will submit toward the end of the decade, not those in flight today; that is exactly why the comparator and sequencing decisions being made for products that will reach the EU under the new Art. 81 of the Directive are the ones that fix eligibility under it.
Art. 81 of the Directive sits atop the Art. 80 of the Directive baseline and provides for discretionary 12-month prolongations of the regulatory market protection period. The compromise text reads through a series of trilogue-flattened amendments, with deleted and inserted phrasing visible side by side in the published Council document; the operative architecture is nevertheless recoverable from the EP press release and from contemporaneous law-firm commentary on the trilogue outcome.3Pharma Package Directive (n 2), Art. 81(2) and Art. 82(1); EP press release of 11 December 2025; M Meulenbelt and others, ‘EU Pharma Package: Sharp New Tools With Limited Protections’ (Sidley Austin LLP, 18 December 2025), on the 8+1+1 architecture and the alternative-paths reading of the comparator-themed limbs. The first prolongation, under Art. 81(2)(a) of the Directive, is conditioned on the applicant demonstrating at the time of the initial marketing authorisation application that the medicinal product addresses an unmet medical need within the meaning of Art. 83 of the Directive, with Art. 82(1) of the Directive acting as a continuous-supply gate on that bonus rather than as its trigger. The second, under Art. 81(2)(b) of the Directive, requires for products containing a new active substance both that the clinical trials supporting the application used a relevant and evidence-based comparator agreed through EMA scientific advice and that the EU marketing authorisation application was filed within 90 days of any first non-Union filing. The third, under Art. 81(2)(c) of the Directive, pairs the comparator condition with a multi-Member-State trial-design condition in lieu of the 90-day rule. A fourth, under Art. 81(2)(d) of the Directive, applies where the applicant has justified that a comparator is not possible or appropriate and combines the multi-Member-State and 90-day-filing conditions; the text provides that this prolongation may be granted only once. Each individual prolongation adds 12 months. A separate 12-month prolongation under Art. 81(2a) of the Directive is available for new therapeutic indications that bring a significant clinical benefit in comparison with existing therapies, where authorisation for the new indication is obtained during the regulatory data protection period; this prolongation, too, may be granted only once. Art. 81(2b) of the Directive caps cumulative regulatory market protection at two years from RDP expiry, except where the Art. 81(2a) of the Directive supra-cap year is added on top. The cap math is therefore determinative: a sponsor can claim at most one of the (a)/(b)/(c)/(d) bonus paths (any combination would exceed the two-year RMP cap), and can stack the Art. 81(2a) of the Directive new-indication bonus above the cap, reaching the trilogue’s 11-year combined ceiling.4Pharma Package Directive (n 2), Art. 81(2b) (cumulative RMP cap of two years from RDP expiry) and Art. 81(2a) (supra-cap 12-month new-indication bonus); a separate Art. 80(4) suspension applies under Regulation (EU) 2025/2645 on compulsory licensing for crisis management.
The bonus is procedural, not substantive. It is captured or forfeited at the order-of-filing decision long before the EMA touches the dossier, and its co-conditions trace back to evidence-package design choices made three to five years earlier.
Three implications follow. First, the (a)/(b)/(c)/(d) bonus paths are mutually exclusive: any two of them in combination would exceed the Art. 81(2b) of the Directive two-year RMP cap, so capturing one forecloses the others. The Art. 81(2a) of the Directive new-indication bonus is the only stackable prolongation, sitting above the cap by express derogation. Second, the prolongations are conditioned on facts the EMA can verify only after the fact (timing of the non-Union filing, the comparator used in the pivotal trials, the Member-State distribution of the clinical-trial sites, the unmet-medical-need profile of the indication); the bonus is granted in the variation procedure once the conditions are documented, not by the assessment committees on the substantive strength of the dossier. Third, the conditions do not align with the trial-design timeline. Phase III comparator decisions are typically made three to five years before MAA submission; Member-State distribution of pivotal-trial sites is locked in by site activation 12 to 24 months earlier; the EU-filing date is set at the end of the development programme. The constraints run backwards along the development chain. A sponsor reaching the MAA-sequencing decision with a placebo-controlled US-anchored pivotal trial and no unmet-medical-need claim has already foreclosed every Art. 81(2) of the Directive prolongation path.
2. The 90-Day Trigger: What “First MAA Outside the Union” Means in Practice
The text of the 90-day rule appears twice in Art. 81(2) of the Directive, first as Art. 81(2)(b)(ii) and again as Art. 81(2)(d)(ii). Each instance uses the same wording: “the marketing authorisation application has been first submitted to the competent authority in the Union or has been submitted no later than 90 days after the submission of the application for the first marketing authorisation outside the Union”.5Pharma Package Directive (n 2), Art. 81(2)(b)(ii) and Art. 81(2)(d)(ii) (the 90-day filing condition; identical wording in both subparagraphs). For the new-active-substance products these bonuses reach, the Union filing is in practice the centralised application to the EMA, so “the competent authority in the Union” is the Agency rather than any national regulator. Three operative components require unpacking before a US sponsor can model the rule against its actual filing patterns.
The first is what counts as “the application for the first marketing authorisation outside the Union”. The Directive does not define the phrase, and the obvious candidates are heterogeneous. A US New Drug Application or Biologics License Application is a national marketing authorisation application filed with the FDA. A Swissmedic MAA filed under the HMG is, in EU-law terms, a third-country marketing authorisation application; Switzerland is not a Member State and is not part of the European Economic Area. A UK MHRA Marketing Authorisation Application post-Brexit is similarly extraterritorial. So is a Japan PMDA MAA, an Australian TGA submission, a Brazil ANVISA filing. The text contains no carve-out for any particular extraterritorial jurisdiction and no priority among them; the operative event is the first submission anywhere outside the Union. A US sponsor’s filing diary that has tracked “US-first” without distinguishing among non-EU jurisdictions will require recalibration before this article applies.
The second is what counts as “submission”. The Directive uses “submitted” rather than the more elaborate “validated” or “accepted for filing”. For the EU clock, that wording suggests the date of submission to the relevant competent authority, not the date of validation. For the non-Union start of the clock, FDA NDA submission dates are tracked by FDA receipt; Swissmedic submission dates are recorded by Swissmedic’s eSubmission portal; the equivalent dates in other jurisdictions vary. Where a sponsor’s submission date and the regulator’s filing-receipt date differ for procedural reasons (a clarification request that returns the dossier to the sponsor, a procedural rejection that requires resubmission), the article’s wording does not resolve which event is operative. The genuine interpretive uncertainty here is not whether the rule applies; it is when the 90-day clock begins.
The third is the status of withdrawn or refused non-Union applications. The rule refers to “the application for the first marketing authorisation outside the Union”, in the singular and without modification. If a sponsor withdraws a US NDA after a Refuse-to-File determination and resubmits months later, did the first submission start the clock, or was it a procedural non-event? If the FDA issues a Complete Response Letter and the sponsor restarts the review cycle, does the original NDA submission remain the operative trigger? The Directive text does not address these scenarios, and the EMA scientific guidelines that Art. 81(3) of the Directive envisages (specifically in respect of the comparator condition under (2)(c)) do not yet exist as of this article’s publication date.
There is a structural point that frames all three of the above. The 90-day requirement runs from submission to submission, not from approval to submission. A sponsor cannot game the rule by waiting for FDA approval before filing in the EU; the clock starts at FDA submission, regardless of how the FDA review eventually resolves. The traditional commercial logic of holding the EU dossier until the FDA approval signal has resolved is now structurally penalised at 12 months of EU market protection, on conditions that the sponsor will have already locked in years before the FDA approval signal even arrives. A parallel but distinct rule operates for priority antimicrobials under Art. 40(4)(c) of the Regulation, which uses a 180-day window rather than 90 days and which conditions the transferable data exclusivity voucher (TEV) rather than the Art. 81(2) of the Directive prolongations.6Council compromise text for the revised Regulation, Council doc ST-6366/26 (24 February 2026), Art. 40(4)(c) (180-day filing rule for priority-antimicrobial TEVs), Art. 41 (TEV transfer mechanics and EUR 490m blockbuster cap), Art. 19 (conditional MA framework). A reader who has seen the 180-day figure in industry commentary should not assume it governs the 90-day bonus discussed here; the two are structurally similar but distinct in scope and beneficiary, and the TEV, including its unresolved interaction with the 11-year cap, is the subject of the forthcoming article 35 (Transferable Exclusivity Vouchers) in this Pharma Package series.
3. Comparative Clinical Trials and Multi-MS Trials as Co-Conditions
The 90-day filing rule never operates alone. In Art. 81(2)(b)(ii) of the Directive it is paired with the comparator condition in (b)(i); in Art. 81(2)(d)(ii) of the Directive it is paired with the multi-Member-State condition in (d)(i) and a justification that a comparator is not possible or appropriate. The third bonus that uses comparator design as a trigger, Art. 81(2)(c) of the Directive, pairs the comparator condition with the multi-Member-State condition without invoking the 90-day rule. The result is a three-path architecture, each route available only for medicinal products containing a new active substance: comparator-plus-90-days; comparator-plus-multi-MS; or no-comparator-but-multi-MS-plus-90-days. A sponsor unable to satisfy any of the three has no Art. 81(2) of the Directive prolongation route open through the comparator family; the only remaining 12-month bonus is the unmet-medical-need Art. 81(2)(a) of the Directive bonus, itself gated by the continuous-supply condition under Art. 82 of the Directive.
What counts as a “relevant and evidence-based comparator in accordance with the scientific advice provided by the Agency” is not defined in the Directive. Recital 52 frames the bonus as an incentive for the inclusion of an evidence-based existing treatment as a comparator “in line with a scientific advice by the Agency”, intended to support subsequent health-technology assessment and pricing-and-reimbursement decisions by Member States.7Pharma Package Directive (n 2), Recitals 52 and 52a (comparative-clinical-evidence rationale and the EMA scientific-advice support role). The Recital does not commit to whether superiority, non-inferiority, or merely the use of an active comparator suffices; the operative determination is delegated to EMA scientific-advice procedures and will be set in guidelines the Agency is required to issue under Art. 81(3) of the Directive. A sponsor that has not engaged EMA scientific advice on its Phase III comparator before MAA submission has no documentary basis on which to claim the (b) or (c) bonus, regardless of how strong the pivotal-trial comparator design is on its substantive merits.
The multi-Member-State condition is equally undefined in the Directive text. Art. 81(2)(c)(ii) and Art. 81(2)(d)(i) of the Directive refer to clinical trials “conducted in more than one Member State”, but the operative criterion is unspecified: minimum number of Member States, minimum number of subjects per Member State, treatment of Member States whose participation was administrative rather than substantive, treatment of Member States that joined the Union mid-trial. The EU Clinical Trials Regulation governs the conduct of such trials through the Clinical Trials Information System (CTIS) and establishes the lead-Member-State coordination architecture for multi-site trials, but it does not establish a typology of multi-MS trials for Pharma Package bonus purposes; the Pharma Package introduces a new operational concept and pushes the substantive definitional work to forthcoming EMA guidelines.8Regulation (EU) No 536/2014 of 16 April 2014 on clinical trials on medicinal products for human use [2014] OJ L158/1 (Clinical Trials Regulation, CTR), Art. 5 (lead Member State coordination) and Art. 81 (CTIS).
The temporal asymmetry between the comparator-design decision and the bonus eligibility is the practical operating constraint. A pivotal-trial comparator is selected at the protocol-design stage, on the basis of regulatory advice received in the same window. A sponsor that designed a Phase III in 2022 or 2023 against the FDA’s preferred placebo-controlled or active-controlled standard, intending the same protocol to support the EU MAA, may discover at the 2026 or 2027 MAA-sequencing decision that the FDA-preferred comparator does not satisfy the EU bonus condition because there is no contemporaneous EMA scientific-advice document supporting it. The protocol that satisfies the FDA does not, in that scenario, satisfy the bonus criterion; and the protocol cannot be reopened at MAA stage. A sponsor reaching the 90-day decision with a comparator design that pre-dates EMA engagement is reaching it with a closed door.
For the (b) path the two conditions are independent locks, set by different functions at different times: the comparator is fixed by clinical development at protocol design, the filing date by regulatory affairs at the end of the programme. Satisfying one does nothing to preserve the other. A sponsor can hold a bonus-qualifying comparator and still forfeit (b) by missing the 90-day window, or hit the window with a comparator the Agency never agreed; only the programme that has aligned both functions, set years apart, captures the bonus.
The operational lead time required to assemble the underlying EMA scientific-advice documentation is itself a binding constraint. The EMA’s Scientific Advice Working Party operates on roughly 70-day written-procedure cycles for standard requests; advice via discussion meeting extends the window to several months; the joint EMA-HTA scientific-advice procedure under the HTA Regulation framework requires earlier engagement and a longer cycle still. For a sponsor that has not started scientific advice on the comparator before locking the Phase III protocol synopsis, the documentation required to support the (b) or (c) prolongation cannot retroactively be assembled. The Art. 81(2) of the Directive bonus and the HTA Joint Clinical Assessment (JCA) dossier built under the HTA Regulation pull in the same operational direction: the JCA mechanism, which has been operative for oncology and advanced-therapy medicinal products since 12 January 2025 and which extends to orphan medicinal products in 2028 and to all centrally authorised products in 2030, requires comparator evidence aligned with health-technology-assessment-body expectations.9Regulation (EU) 2021/2282 of the European Parliament and of the Council of 15 December 2021 on health technology assessment [2021] OJ L458/1 (HTA Regulation), establishing the JCA mechanism for oncology and ATMPs from 12 January 2025. US sponsors building dossiers aligned to FDA preferences without parallel EMA and HTA engagement are foreclosing both the Art. 81(2) of the Directive bonus eligibility and the JCA evidence package; sponsors investing in EMA scientific advice and HTA-aligned comparator design are simultaneously building both. The two requirements are operationally aligned but the alignment is invisible to a sponsor that treats them as separate workstreams.
4. Swiss Filing, FDA Filing, and the Sequence That Captures or Forfeits the Bonus
Three filing patterns dominate the global launch sequencing of US originators, and each interacts with the 90-day rule differently. The first is the FDA-first sequence: NDA or BLA to the FDA, then a Swissmedic MAA under the HMG after the FDA review converges on approval signals, then the EMA MAA after Swissmedic.10Bundesgesetz über Arzneimittel und Medizinprodukte (Heilmittelgesetz, HMG) vom 15. Dezember 2000 (SR 812.21); Switzerland’s bilateral MRA with the EU covers GMP inspections but not MAA recognition. The second is the parallel-track sequence: simultaneous FDA and EMA filings. The third, often used for assets with strong Swiss commercial profile, is the Swissmedic-first or Swissmedic-early sequence, leveraging Swissmedic’s standard validation timeline and Switzerland’s favorable pricing dynamics relative to most EU Member States.
Under the pre-Pharma-Package regime, the choice between these patterns was substantively jurisdiction-independent for regulatory-protection purposes. The EU’s prior 8+2(+1) RDP architecture under Directive 2001/83/EC did not condition the bonus year on filing sequencing; the bonus accrued, where it accrued, on the basis of new-therapeutic-indication evidence demonstrated at EMA assessment. Switzerland was a separate decision, governed by HMG commercial timing and the foreign-reference-pricing rules administered by BAG under the KVV framework. The new Art. 81(2)(b)(ii) and (d)(ii) of the Directive collapse those decisions: every Swissmedic, MHRA, FDA, PMDA, or other non-EU filing is, structurally, “outside the Union” for bonus purposes, and the first such filing starts the 90-day clock.
The Swissmedic-first scenario is the clearest illustration of the structural shift. Switzerland is not a Member State of the EU and is not part of the European Economic Area; the bilateral pharmaceutical Mutual Recognition Agreement between Switzerland and the EU governs conformity assessment for Good Manufacturing Practice inspections but does not extend Swiss MAA filings into the EU regulatory perimeter. A Swissmedic MAA is therefore unambiguously “outside the Union” for Art. 81(2)(b)(ii) of the Directive purposes. For a US sponsor that files with Swissmedic in week 1 and reaches EU readiness only in week 30, on a straightforward reading of Art. 81(2)(b)(ii) and (d)(ii) of the Directive the EU filing falls outside the 90-day window and the (b) and (d) bonus paths would not be available, pending EMA scientific guidelines that may yet refine the clock-start mechanics. A Swissmedic-early sponsor that files the EU marketing authorisation application within 90 days of the Swiss submission keeps those paths open; it is the gap, not the Swiss-first sequence as such, that forfeits the bonus. The commercial logic that has historically supported Swissmedic-first filings, faster review windows and the prospect of an authorised Swiss label that supports cantonal pricing negotiations and foreign-reference-price positioning, is unchanged on the Swiss revenue side but, under the new architecture, carries a 12-month EU exclusivity cost that did not exist before.
The FDA-first sequence is the more common pattern and the more analytically interesting. A US sponsor’s NDA or BLA submission to the FDA is the operative trigger; once submitted, the EU clock has 90 days. The EU dossier must be substantively ready at FDA submission, not at FDA approval. The Common Technical Document modules submitted to the FDA are a substantial overlap with the EU MAA dossier, but the EU-specific modules (Module 1 in EU format, the EU summary of product characteristics, EU-specific risk-management plan content, environmental risk assessment documentation, Member-State-specific labeling) are non-trivial. A development programme that has not parallelised EU-readiness work alongside the FDA-submission work has, in practice, no realistic prospect of meeting the 90-day window after FDA filing has occurred.
The parallel-track FDA-plus-EMA sequence is the structural workaround. If both applications are submitted on the same day, neither is “first” relative to the other in any meaningful sense, and the 90-day rule does not bite as between those two regulators; the operative question becomes the first non-Union filing in any other jurisdiction. This option, traditionally avoided by US sponsors for resource-allocation reasons (the EU dossier is large, the regulatory-affairs team is sized for sequential filings, and the FDA-review uncertainty argues against committing to the EU dossier before FDA signals are received), carries a quantifiable bonus-preservation value under the new architecture. Whether that value, twelve months of EU market protection on a successful product, justifies the carrying cost of a fully EU-ready dossier six to twelve months earlier than the sponsor would otherwise have it is a deal-specific calculation that the Art. 81 of the Directive architecture pushes onto every US sponsor with an EU launch plan, not only those that had been considering parallel filings on commercial grounds. The carrying cost of standing EU-readiness amortises across a multi-asset pipeline but falls on a single product for the one-asset biotech, so the operating-model investment tilts toward sponsors with several EU launches in view and against those with one.
Two further filing-sequence variables warrant brief mention. Japan PMDA submissions are also “outside the Union” for Art. 81(2)(b)(ii) and (d)(ii) of the Directive purposes; US sponsors with strong Asian commercial profiles in oncology and rare diseases, where a Japan-first or Japan-early sequence has historically supported price-anchoring against Japan’s NHI fee schedule, must apply the same 90-day clock starting at PMDA submission that the article’s Swiss-first analysis applies to Swissmedic. EMA PRIME designation, by contrast, operates inside the Union and does not trigger the clock; what PRIME does do is shorten the EMA’s review path and presuppose the kind of early EMA engagement that materially improves the operational feasibility of meeting a 90-day window after FDA submission. A US sponsor that has secured PRIME for an asset is structurally closer to bonus-path eligibility than one operating outside PRIME, even though PRIME itself confers no entitlement to the Art. 81(2) of the Directive prolongation.
The Art. 81(2)(a) of the Directive bonus carries its own Member-State-level relief valve that sponsors with sub-economic small-Member-State supply profiles should understand. Recital 56 of the Directive permits a Member State to waive the launch condition that gates the (a) bonus, ordinarily issued through a statement of non-objection, particularly where launch in that Member State is materially impossible or where special reasons cause the Member State itself to prefer a later launch. For a US sponsor whose commercial model cannot economically supply a Maltese or Estonian market in the absence of a meaningful tender, the waiver mechanism is the difference between (a)-bonus eligibility (subject to securing the waivers from non-supplying Member States) and forfeiture; sponsors that treat the supply condition as an all-or-nothing technical requirement are leaving the waiver mechanism unused. The mechanism is not self-executing, and the Recital 56 reference does not specify timelines or procedural form for the statement of non-objection; whether a sponsor can secure the necessary waivers from non-supplying Member States in time for the variation procedure that triggers the bonus determination is itself an open question.
5. Strategic Considerations for US Sponsors
The architectural change Art. 81 of the Directive introduces is procedurally simple and operationally far-reaching. A sponsor whose comparator-design and Member-State-distribution decisions were taken during 2022 to 2024, before the Pharma Package’s final shape was visible at trilogue, now faces a question that was not on the table at protocol-design time: whether to re-sequence the global launch around the EU 90-day window where the upstream design choices still permit it, or to accept the forfeiture of a year of EU market protection that the Art. 81(2)(b) or (d) of the Directive bonus path would, in principle, have made available. The bonus year typically falls in years 10 and 11 of the product lifecycle, when revenue is at or near peak and the marginal cost of an additional twelve months of protected sales approaches zero. The decision to re-sequence or to forfeit is a board-level commercial decision that the regulatory architecture has shifted upstream of where US in-house counsel are accustomed to encountering it.
Where a portfolio contains both bonus-eligible and bonus-ineligible assets, the calculus pulls in opposite directions. A comparator-design rare-disease asset with multi-MS pivotal trials may be a strong candidate for the (b) or (c) path; a placebo-controlled mass-market asset whose Phase III was finalised against FDA scientific advice without parallel EMA engagement may be a weaker candidate, and the question is whether the cost of internal coordination to capture the bonus on the eligible assets justifies a coordination overhead that affects portfolio-wide regulatory operations. The licensing implications are material: a development-stage out-licensing deal struck on the assumption of a bonus-captured EU exclusivity has different milestone economics than one struck assuming bonus forfeiture, and the M&A valuation of a development-stage asset whose pivotal-trial comparator is already locked is newly sensitive to a regulatory parameter that prior diligence frameworks have not surfaced. A buyer can detect that parameter in diligence but, once the pivotal trials are enrolled, can no longer cure it. A separate calculus applies where an asset qualifies for the Art. 81(2)(a) of the Directive unmet-medical-need bonus: under the Art. 81(2b) of the Directive two-year RMP cap, capturing the (a) bonus consumes the sponsor’s ability to also capture any of the comparator-themed (b), (c), or (d) bonuses, since the (a) limb fills the same one-year-of-extension slot that (b)/(c)/(d) would otherwise fill. For those assets the 90-day filing rule’s strategic salience drops sharply; the sequencing question instead focuses on Art. 82(1) of the Directive supply-continuity execution and on the Art. 81(2a) of the Directive new-indication bonus that remains stackable above the cap.
A different strategic question presents itself where a US sponsor anticipates entering the EU through the Pharma Package’s conditional-marketing-authorisation pathway, which EMA’s PRIME designation routinely funnels assets into. Art. 81(2) of the Directive carries a specific carve-out for conditional MAs granted under Art. 19 of the companion Regulation: the (a) prolongation will only attach if the conditional MA is converted to a full marketing authorisation under Art. 19(7) of the Regulation within four years of the conditional grant, and (for products invoking the Art. 83(1)(b) of the Directive limb of unmet medical need) the post-authorisation studies referenced in Art. 19(4) of the Regulation must include clinical trials that use, where possible and appropriate, a relevant and evidence-based comparator.11Pharma Package Directive (n 2), Art. 81(2) end-subparagraph (conditional-MA carve-out), with Art. 19, Art. 19(4) and Art. 19(7) of the companion Pharma Package Regulation (n 6). The cliff is operational, not procedural: a sponsor relying on the conditional pathway to reach EU patients quickly under PRIME must also commit, at conditional grant, to a confirmatory study programme that closes within four years and (where the unmet-need limb is invoked) carries the comparator design the post-grant cleanup will demand. US sponsors that have not historically planned confirmatory studies on a four-year clock will discover the cliff at conversion, when the (a) bonus is structurally lost rather than negotiable.
The analysis above tracks the RDP-plus-RMP architecture that governs non-orphan medicinal products. Orphan-designated assets, which represent a substantial fraction of US biotech’s most valuable pipelines, sit on a different protection track entirely. Under the Pharma Package’s orphan provisions, the operative period is a market exclusivity of nine years for standard orphan medicinal products and eleven years for “breakthrough” orphan medicinal products addressing a disease for which no medicinal product is authorised in the Union, granted on a product-based rather than indication-based footing.12Pharma Package Regulation (n 6), Chapter VI, Art. 63 ff., establishing the orphan-designation framework, the breakthrough qualification at Art. 70, and the market-exclusivity periods at Art. 71. The 90-day filing rule discussed in this article does not condition the orphan exclusivity period, although the underlying filing-sequence question (FDA-first, Swissmedic-first, parallel, EMA-first) does interact with the orphan-track approval timing. US biotechs with orphan-designated lead assets should treat the analysis here as the framework that applies to their non-orphan portfolio segments and to indication expansions that fall outside the orphan designation; the orphan-track architecture is the subject of the forthcoming article 32 (The New Orphan Math) in this Pharma Package series.
The Swissmedic-first commercial logic is in particular tension with the new architecture. Sponsors with strong Swiss commercial profiles, where Switzerland’s BAG SL listing economics and cantonal pricing produce revenue acceleration, have historically treated Swissmedic-first as value-creating independent of EMA timing. Whether that calculation still holds turns on whether the Swiss revenue acceleration between Swissmedic and EMA approval compensates for the 12 months of EU market protection structurally forfeited a decade later, a question that depends on product trajectory, EU pricing under the simultaneous access-conditionality reforms, and discount-rate treatment of cash flows separated by years. There is no general answer.
The deepest question may be the retroactive one. At what point does an evidence-package decision made years earlier become the binding constraint on the sponsor’s ability to capture the bonus at all? For pivotal trials already enrolled and approaching readout, the comparator design is fixed. For trials in protocol design at the time of this article’s publication, the comparator decision is the operative one, and the answer requires alignment between regulatory-affairs and the commercial team well before the protocol synopsis is finalised. For programmes still in Phase II planning, the choice is between designing the pivotal-trial architecture around the bonus criteria from the outset, accepting the EMA scientific-advice overhead and the comparator constraints, or optimising the protocol for FDA approval timeline and accepting that the Art. 81(2) of the Directive path is closed on the EU side. The architecture that determines whether the bonus can be captured is now upstream of the regulatory team and inside the commercial development plan, in a position where US in-house counsel without an EU or Swiss legal team typically do not encounter EU regulatory architecture at all until the bonus has already been lost.